Pfizer's stock has suffered a brutal 16.44% drop in April, despite flexing strong Q4 earnings with a 37.2% EPS beat. Over the ...

It also offers a high dividend yield of about 8%, which could help keep the stock price from falling much further. The BofA analyst notes that the long-term growth outlook is weaker than average due ...

BofA lowered the firm’s price target on Pfizer (PFE) to $26 from $29 and keeps a Neutral rating on the shares. For Q1, the firm’s total revenue ...

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

Pfizer shares inched up 0.4% on Friday, riding a surge in trading volume that was 33% above average—call it a micro-win. Wall ...

We recently published a list of Jeff Smith’s Top 10 Activist Targets and Their Returns Compared to the S&P 500. In this ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly’s latest innovation, orforglipron, has emerged as a formidable contender in the weight-loss medication arena. The pill has demonstrated comparable results to Ozempic, a leading injectable ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 5.89%, which has investors questioning if this is right time to ...